Th Chop News Today

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

The floor begging for mercy. this is work goes with these ridiculous campaigns. so my message to you, just you had your chance at three. come in for four forge were fired. go to one of the sweatshops in china. >> this story reminds me of you. you started working at fox -- with the opposite. when people at this lazy or thi in title, there are people like you who see that like, oh, i used to come to progress for th chop job he wanted, remember. you work for the huckabee show. >> with my first show...